<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest announcement is out from Vaxart ( (VXRT) ). On April 23, 2026, Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines using a proprietary pill-based delivery platform, said it had appointed veteran biotech executive James B. Breitmeyer, M.D., Ph.D., to its Board of Directors. Vaxart’s pipeline targets coronavirus, norovirus, influenza and a therapeutic HPV indication, with vaccines designed for room-temperature storage and needle-free administration. The appointment brings more than three decades of clinical development and regulatory experience to Vaxart’s board, including leadership roles at Oncternal Therapeutics, Bavarian Nordic, Eli Lilly and other biopharma companies, where Breitmeyer contributed to multiple FDA approvals and vaccine programs. Vaxart’s directors said his background in drug and vaccine development is expected to reinforce oversight of its clinical programs and support advancement of its oral vaccine platform as the company works to validate the benefits of its technology for patients and investors. The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page. Spark’s Take on VXRT Stock According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral. The score is driven mainly by the improved TTM financial profile (rapid revenue growth and a return to profitability/positive cash flow), tempered by concerns about sustainability given historically volatile results and a smaller equity cushion. Technicals are supportive with the stock above key moving averages, while valuation looks inexpensive on P/E but lacks dividend support and relies on potentially non-recurring earnings. Earnings call factors are constructive due to partnership validation and extended runway, but remain risk-weighted due to BARDA-related delays and partner-dependency. To see Spark’s full report on VXRT stock, click here. More about Vaxart Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines using a proprietary pill-based delivery platform. Its vaccines are designed to be stored and shipped without refrigeration and target indications including coronavirus, norovirus, influenza and a therapeutic human papillomavirus vaccine, supported by broad domestic and international patent filings. The company aims to create oral versions of currently marketed vaccines and new recombinant vaccines, positioning itself in the vaccine market as a needle-free, more easily distributed alternative. By focusing on adenovirus- and TLR3 agonist-based technologies, Vaxart is pursuing both infectious disease prevention and immune-oncology applications, with a particular emphasis on global accessibility and simplified vaccination logistics. Average Trading Volume: 491,637 Technical Sentiment Signal: Hold Current Market Cap: $182.8M Find detailed analytics on VXRT stock on TipRanks’ Stock Analysis page.</div>

VXRT

ARKG

Vaxart, Inc. has appointed James B. Breitmeyer, M.D., Ph.D., a veteran biotech executive, to its Board of Directors. This move aims to enhance oversight of Vaxart's clinical programs and support the advancement of its oral vaccine platform, which targets various viruses including coronavirus and HPV. The company is known for its innovative pill-based delivery system for vaccines. Analysts currently rate Vaxart's stock (VXRT) as a Buy with a price target of $4.00, although concerns about sustainability and historical volatility remain.

Vaxart Adds Veteran Biotech Leader to Board